Bavarian Nordic A/S (BAVA.VI)

Loading...

Company Overview

Company Name

Bavarian Nordic A/S

Symbol

BAVA.VI

Exchange

Vienna

Daily Change

-0.24%

52 Week Change

-7.11%

52-Week Range

17.915 - 32.520 EUR

Market Cap

1.92B EUR

Sector

-

Industry

Biotechnology

Employees

1,738

Country

Denmark

Business Summary

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, Finland, Netherlands, Switzerland, Sweden, Taiwan, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Market Information

Currency

EUR

First Trade Date

12/22/2022

Regular Market Change

-0.0600 (-0.0024%)

Regular Market Volume

-

Average Daily Volume (3M)

7